98%
921
2 minutes
20
Biomaterials possess distinctive properties, notably their ability to encapsulate active biological products while providing biocompatible support. The immune system plays a vital role in preventing cancer recurrence, and there is considerable demand for an effective strategy to prevent cancer recurrence, necessitating effective strategies to address this concern. This review elucidates crucial cellular signaling pathways in cancer recurrence. Furthermore, it underscores the potential of biomaterial-based tools in averting or inhibiting cancer recurrence by modulating the immune system. Diverse biomaterials, including hydrogels, particles, films, microneedles, etc., exhibit promising capabilities in mitigating cancer recurrence. These materials are compelling candidates for cancer immunotherapy, offering in situ immunostimulatory activity through transdermal, implantable, and injectable devices. They function by reshaping the tumor microenvironment and impeding tumor growth by reducing immunosuppression. Biomaterials facilitate alterations in biodistribution, release kinetics, and colocalization of immunostimulatory agents, enhancing the safety and efficacy of therapy. Additionally, how the method addresses the limitations of other therapeutic approaches is discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsbiomaterials.3c01347 | DOI Listing |
Ann Surg Oncol
September 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background: Hepatocellular carcinoma (HCC) frequently invades the portal vein, leading to early recurrence and a poor prognosis. However, the mechanisms underlying this invasion remain unclear. In this study, we aimed to detect portal vein circulating tumor cells (CTCs) using a Glypican-3-positive detection method and evaluate their prognostic significance.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.
Introduction: The optimal surveillance for mucinous appendix cancer (MAC) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) remains unclear. We identified postoperative periods reflecting significant changes in recurrence probability.
Methods: A prospective database (1998-2024) of patients with stage IV MAC with low-grade (LGMCP), high-grade (HGMCP), and signet-ring cell (SRC) histology treated with initial complete (CC-0/1) CRS/HIPEC was analyzed.
Int J Clin Oncol
September 2025
Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan.
Background: Limited data are available on relative survival (RS) among cancer survivors enrolled in private cancer insurance in Japan. Additionally, the incidence of second primary cancers or recurrences, as applicable, after a certain period remains unclear.
Methods: We analyzed 8,846 cancer survivors, including carcinoma in situ, aged 15-79 years, enrolled in private cancer insurance between April 2005 and September 2021, and diagnosed before April 2022.
Pediatr Surg Int
September 2025
Pediatric Surgery Department, Fattouma Bourguiba University Hospital, Monastir, Tunisia.
Purpose: This meta-analysis compares thoracoscopic versus open thoracotomy repair of esophageal atresia with tracheoesophageal fistula (EA/TEF).
Methods: We systematically searched PubMed, Web of Science, Cochrane Library, and Scopus from inception to April 2025 for studies comparing thoracoscopic versus conventional thoracotomy approaches. Two independent reviewers screened studies, extracted data, and assessed risk of bias using appropriate tools.
Surg Today
September 2025
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8588, Japan.
Purpose: Liver metastases from colorectal cancer (CRLM) are a major determinant of the prognosis of metastatic colorectal cancer. Although curative resection is recommended for resectable CRLM, recurrence remains a challenge and the criteria for patient selection and repeat resection are still unclear. We conducted this study to evaluate the outcomes of metastatic lesion resection with curative intent (R0 resection), to identify the factors associated with recurrence, and to establish the feasibility of repeat metastasectomy.
View Article and Find Full Text PDF